Angita Pharmaceuticals is dedicated to the discovery of novel targets and drug candidates for the treatment of unmet needs in diseases of the Central Nervous System (CNS) and indications in which the CNS plays an important function.
They have a number of projects ongoing and are constantly seeking to increase the diversity of our discovery portfolio through collaborative projects and in-licensing opportunities.
Angita Pharmaceuticals develops novel, patent-protected drug development candidates with strategic focus on CNS indications and those in which the CNS plays a clear regulatory function. They in-license novel IP from academia and adopt a flexible licensing model giving the inventor the opportunity to participate in the drug discovery projects. Other projects in their discovery pipeline come from in-house research activities and via joint projects with collaborative partners.To ensure focus on their discovery projects, development candidates will be out-licensed.